External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021en_US
dc.contributor.authorYekedüz, Emre
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorErtürk, İsmail
dc.contributor.authorTural, Deniz
dc.contributor.authorUçar, Gökhan
dc.contributor.authorÖztaş, Nihan Şentürk
dc.contributor.authorÖzgüroğlu, Mustafa
dc.contributor.authorKüçükarda, Ahmet
dc.contributor.authorSever, Özlem Nuray
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorDemirci, Umut
dc.contributor.authorArıkan, Nuriye
dc.date.accessioned2022-08-19T05:25:38Z
dc.date.available2022-08-19T05:25:38Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: A novel prognostic model was recommended for patients with metastatic RCC (mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to externally validate a novel risk model for the IMDC-favorable risk group in patients with mRCC. Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) is a multicenter registry that includes 13 cancer centers in Turkey. As described by Schmidt et al., 3 parameters (ie, time from diagnosis to systemic therapy <3 vs. ?3 years, Karnofsky Performance Status [KPS] 80 vs. >80, and the presence of brain, liver, or bone metastasis) were used to divide the IMDC favorable risk group into 2 new categories: very favorable and favorable risk groups. The primary endpoint was overall survival (OS). Time to treatment failure (TTF) and objective response rate (ORR) in the very favorable and favorable risk groups were the secondary endpoints. Results: A total of 545 patients with mRCC from all IMDC risk groups and 112 patients from the favorable risk group were included in this study. According to the novel classification model, 44 (39.3%) and 68 (60.7%) patients with former favorable risk were categorized into very favorable and favorable risk groups, respectively. The median OS (55.8 months vs. 34.2 months, P = .025) and TTF (25.5 months vs. 15.5 months, P = .010) were longer in the very favorable risk group than in the favorable risk group. The concordance index of the new IMDC model in all patients was 0.65 for OS. Despite the higher ORR in the very favorable risk group than in the favorable risk group, the difference between the groups was not statistically significant (52.4% vs. 44.7, P = .573). Conclusions: This was the first study to externally validate the novel IMDC risk model presented in the American Society of Clinical Oncology Genitourinary Cancers Symposium 2021.en_US
dc.identifier.citationYekedüz E, Karakaya S, Ertürk İ, Tural D, Uçar G, Şentürk Öztaş N, Arıkan R, Hızal M, Küçükarda A, Sever ÖN, Arslan Ç, Can O, Kılıçkap S, Yazgan C, Karadurmuş N, Ali Şendur M, Çiçin İ, Demirci U, Özgüroğlu M, Öksüzoğlu B, Ürün Y. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Clin Genitourin Cancer. 2022 Jul 16:S1558-7673(22)00158-6. doi: 10.1016/j.clgc.2022.07.006. Epub ahead of print. PMID: 35970759.en_US
dc.identifier.doi10.1016/j.clgc.2022.07.006en_US
dc.identifier.issn1558-7673en_US
dc.identifier.pmid35970759en_US
dc.identifier.scopus2-s2.0-85136765917en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://doi.org/10.1016/j.clgc.2022.07.006
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3108
dc.identifier.wosWOS:000926838900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofClinical Genitourinary Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectRisk Groupsen_US
dc.subjectVery Favorableen_US
dc.titleExternal Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Databaseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
1-s2.0-S1558767322001586-main.pdf
Boyut:
922.32 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu